Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
Yuliya Lytvyn, Petter Bjornstad, Jacob A. Udell, et al.
Circulation (2017) Vol. 136, Iss. 17, pp. 1643-1658
Open Access | Times Cited: 394

Showing 1-25 of 394 citing articles:

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi, et al.
New England Journal of Medicine (2019) Vol. 381, Iss. 21, pp. 1995-2008
Open Access | Times Cited: 5298
Diabetic Cardiomyopathy
Guanghong Jia, Michael A. Hill, James R. Sowers
Circulation Research (2018) Vol. 122, Iss. 4, pp. 624-638
Open Access | Times Cited: 1330
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma, John J.V. McMurray
Diabetologia (2018) Vol. 61, Iss. 10, pp. 2108-2117
Open Access | Times Cited: 789
Heart Failure With Reduced Ejection Fraction
Sean Murphy, Nasrien E. Ibrahim, James L. Januzzi
JAMA (2020) Vol. 324, Iss. 5, pp. 488-488
Closed Access | Times Cited: 525
Calcium Signaling and Reactive Oxygen Species in Mitochondria
Edoardo Bertero, Christoph Maack
Circulation Research (2018) Vol. 122, Iss. 10, pp. 1460-1478
Open Access | Times Cited: 483
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J.L. Heerspink, Mikhail Kosiborod, Silvio E. Inzucchi, et al.
Kidney International (2018) Vol. 94, Iss. 1, pp. 26-39
Open Access | Times Cited: 324
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W. Mahaffey, Meg Jardine, Séverine Bompoint, et al.
Circulation (2019) Vol. 140, Iss. 9, pp. 739-750
Open Access | Times Cited: 267
Cardiovascular Effects of New Oral Glucose-Lowering Agents
André Scheen
Circulation Research (2018) Vol. 122, Iss. 10, pp. 1439-1459
Open Access | Times Cited: 251
Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging
Kengo Kidokoro, David Z.I. Cherney, Andrea Božović, et al.
Circulation (2019) Vol. 140, Iss. 4, pp. 303-315
Open Access | Times Cited: 243
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment
Eva M. Boorsma, Jozine M. ter Maaten, Kevin Damman, et al.
Nature Reviews Cardiology (2020) Vol. 17, Iss. 10, pp. 641-655
Open Access | Times Cited: 241
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
Qingmiao Shao, Lei Meng, Sharen Lee, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 233
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 228
Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy
Nina Kaludercic, Fabio Di Lisa
Frontiers in Cardiovascular Medicine (2020) Vol. 7
Open Access | Times Cited: 226
Protective role of melatonin in cardiac ischemia‐reperfusion injury: From pathogenesis to targeted therapy
Hao Zhou, Qiang Ma, Pingjun Zhu, et al.
Journal of Pineal Research (2018) Vol. 64, Iss. 3
Open Access | Times Cited: 219
Highlights in heart failure
Daniela Tomasoni, Marianna Adamo, Carlo Lombardi, et al.
ESC Heart Failure (2019) Vol. 6, Iss. 6, pp. 1105-1127
Open Access | Times Cited: 212
Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
Giulia Borghetti, Dirk von Lewinski, Deborah Eaton, et al.
Frontiers in Physiology (2018) Vol. 9
Open Access | Times Cited: 195
The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 11, pp. 1402-1411
Open Access | Times Cited: 188
Empagliflozin directly improves diastolic function in human heart failure
Steffen Pabel, Stefan Wagner, Hannah Bollenberg, et al.
European Journal of Heart Failure (2018) Vol. 20, Iss. 12, pp. 1690-1700
Open Access | Times Cited: 184
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure
Natalie Mordi, Ify Mordi, Jagdeep Singh, et al.
Circulation (2020) Vol. 142, Iss. 18, pp. 1713-1724
Open Access | Times Cited: 184
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Pantelis Sarafidis, Charles J. Ferro, Enrique Morales, et al.
Nephrology Dialysis Transplantation (2019) Vol. 34, Iss. 2, pp. 208-230
Open Access | Times Cited: 172
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
Michaël J.B. van Baar, Charlotte C. van Ruiten, Marcel H.A. Muskiet, et al.
Diabetes Care (2018) Vol. 41, Iss. 8, pp. 1543-1556
Open Access | Times Cited: 170
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
Motoaki Sano
Journal of Cardiology (2018) Vol. 71, Iss. 5, pp. 471-476
Open Access | Times Cited: 165
Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure
Senthil Selvaraj, Daniel P. Kelly, Kenneth B. Margulies
Circulation (2020) Vol. 141, Iss. 22, pp. 1800-1812
Open Access | Times Cited: 158
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
Koenraad Philippaert, Subha Kalyaanamoorthy, Mohammad Fatehi, et al.
Circulation (2021) Vol. 143, Iss. 22, pp. 2188-2204
Open Access | Times Cited: 157
Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
Husam Ghanim, Sanaa Abuaysheh, Jeanne Hejna, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 4, pp. e1056-e1063
Open Access | Times Cited: 154
Page 1 - Next Page

Scroll to top